Clinical trials: Activating EGFR Mutation
Non-Small Cell Lung Cancer, Leptomeningeal Metastases
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or…
- Conditions
- Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
- Trial name
- NCT02616393
- Testing
- Tesevatinib
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Kadmon Corporation, LLC
NSCLC
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
This is a randomized, open-label, controlled, multicenter, Phase III study. Patients will be randomly assigned to treatment group (1:1) through a dynamic randomization process with use of the following stratification factors: sex…
- Trial name
- NCT02759614
- Testing
- Bevacizumab, Erlotinib
- Where
- China
- Volunteers
- 311 people
- Sponsor
- Guangdong Association of Clinical Trials
ALK Gene Translocation, EGFR Activating Mutation
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of plinabulin when given together with nivolumab and to see how well they work in treating patients with stage IIIB-IV non-small cell lung cancer that has come back or…
- Conditions
- ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation
- Trial name
- NCT02846792
- Testing
- Nivolumab, Plinabulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Non-small Cell Lung Cancer (NSCLC)
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or…
- Trial name
- SOLAR (NCT02588261)
- Testing
- naquotinib mesilate, Erlotinib, Gefitinib
- Where
- 167 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR…
- Trial name
- NCT05258279
- Testing
- Pembrolizumab, Lenvatinib, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Juntendo University
Lung Cancer
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Advanced stage lung cancer is generally treated with anti-cancer medication called chemotherapy. Most lung cancer is caused by cigarette smoking.
- Trial name
- NCT00988169
- Testing
- oral erlotinib and pulsed doses of oral AT-101
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)…
- Trial name
- NCT01260181
- Testing
- Erlotinib
- Where
- 9 sites in Portugal
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer, Stage III NSCLC
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
Previous clinical studies showed there is a potential value of EGFR-TKI in local advanced EGFR-mutant NSCLC, while the risk of radiation pneumonia in combination of EGFR-TKI with thoracic radiotherapy is unknown.
- Conditions
- Non Small Cell Lung Cancer, Stage III NSCLC, EGFR Activating Mutation
- Trial name
- NCT04636593
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- First People's Hospital of Hangzhou
Non-small Cell Lung Cancer
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR)…
- Trial name
- RECEL (NCT01714908)
- Testing
- Erlotinib w Concurrent Radiotherapy, etoposide/cis-platin (EP) w Concurrent Radiotherapy
- Where
- 19 sites in China
- Volunteers
- 100 people
- Sponsor
- Jinming Yu
Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
This study is an open-label, multicenter, single-arm clinical study.
- Conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation, PD-1 Antibody
- Trial name
- NCT07637448
- Testing
- EGFR-TKIs Combined with PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Carcinoma, Non-Small-Cell Lung
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
This study aimed to evaluate the anticancer activity of capmatinib in combination with osimertinib compared to platinum-pemetrexed based doublet chemotherapy as second line treatment in patients with advanced or metastatic…
- Trial name
- GEOMETRY-E (NCT04816214)
- Testing
- Capmatinib, Osimertinib, Pemetrexed
- Where
- 4 sites in Japan, Singapore and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin…
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT05241873
- Testing
- BLU-451, Carboplatin, Pemetrexed
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Blueprint Medicines Corporation
NSCLC, Leptomeningeal Metastasis
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.
- Conditions
- NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation
- Trial name
- ATTRACT (NCT04944069)
- Testing
- Almonertinib, Bevacizumab
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Neoplasms
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.
- Trial name
- NCT00748709
- Testing
- BIBW 2992 (Afatinib)
- Where
- 15 sites in United States, Taiwan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
This open-label study will assess the efficacy and safety of Tarceva (Erlotinib) in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who have not received previous chemotherapy for their disease…
- Trial name
- NCT01372384
- Testing
- erlotinib [Tarceva]
- Where
- 9 sites in Bulgaria
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer
This is a Phase 1/2, open-label, multicenter, sequential dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-e4 administered orally in subjects with advanced non-small…
- Trial name
- NCT03446417
- Testing
- ZN-e4
- Where
- 7 sites in United States, Bosnia and Herzegovina
- Volunteers
- 34 people
- Sponsor
- Zeno Pharmaceuticals, Inc.
Lung Adenocarcinoma, EGFR Activating Mutation
Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations.
- Trial name
- NCT06730477
- Testing
- observational study
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NSCLC
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.
- Trial name
- NCT05463224
- Testing
- Lazertinib group
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Sehhoon Park
Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations
- Trial name
- NCT05364073
- Testing
- Furmonertinib
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 160 people
- Sponsor
- ArriVent BioPharma, Inc.